Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | NTSR2 | O95665 | 3/20 | 0.53 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.53 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22400261 | 1.00 | OPRM1 (0.55) | OPRM1OPRD1OPRK1SLC6A2NTSR2 | |
| SCHEMBL1674814 | 1.00 | OPRM1 (0.55) | OPRM1OPRD1OPRK1SLC6A2NTSR2 | |
| SCHEMBL1674802 | 0.94 | NMUR2 (0.57) | OPRM1OPRD1OPRK1SLC6A2NTSR2 | |
| SCHEMBL1674805 | 0.94 | NMUR2 (0.57) | OPRM1OPRD1OPRK1SLC6A2NTSR2 | |
| SCHEMBL31377408 | 0.94 | SLC6A2 (0.57) | OPRM1OPRD1OPRK1SLC6A2F2 | |
| Leucine SCHEMBL14969488 | 0.93 | NMUR2 (0.56) | OPRM1OPRD1OPRK1SLC6A2NTSR2 | |
| SCHEMBL29531518 | 0.92 | SLC6A2 (0.55) | OPRM1OPRD1OPRK1SLC6A2F2 | |
| SCHEMBL29836800 | 0.91 | SLC6A2 (0.56) | OPRM1OPRD1OPRK1SLC6A2 | |
| SCHEMBL28915426 | 0.91 | NMUR2 (0.58) | OPRM1OPRD1OPRK1SLC6A2NTSR2 | |
| SCHEMBL28915423 | 0.91 | NMUR2 (0.58) | OPRM1OPRD1OPRK1SLC6A2NTSR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2661266-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | Elcelyx Therapeutics, Inc. (US) | 2013-11-13 | — | — | EP | claimed |
| WO-2012094636-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | WO | claimed |
| US-11758933-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2023-09-19 | — | — | US | disclosed |
| US-11357246-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
| US-20210227863-A1 | HIGH INTENSITY SWEETENERS | SENOMYX, INC. | 2021-07-29 | — | — | US | disclosed |
| EP-3763419-A1 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | Anji Pharma (US) LLC (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-2661266-B1 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ANJI PHARMA (US) LLC (US) | 2020-09-16 | — | — | EP | disclosed |
| US-10610500-B2 | Chemosensory receptor ligand-based therapies | ANJI PHARMA (US) LLC (US) | 2020-04-07 | — | — | US | disclosed |
| US-10392371-B2 | Compounds useful as modulators of TRPM8 | SENOMYX, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190177308-A9 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | SENOMYX, INC. | 2019-06-13 | — | — | US | disclosed |
| US-20190038576-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2019-02-07 | — | — | US | disclosed |
| WO-2012094636-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | WO | disclosed |
| US-20120177730-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2012054528-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20110177545-A1 | G-PROTEINS | GIVAUDAN SA (CH) | 2011-07-21 | — | — | US | disclosed |
| US-7919236-B2 | G-proteins | GIVAUDAN SA (CH) | 2011-04-05 | — | — | US | disclosed |
| EP-1581555-B1 | CHIMERIC ALPHA Q-GUSTDUCIN G-PROTEINS | GIVAUDAN SA (CH) | 2008-04-30 | — | — | EP | disclosed |
| US-20060275765-A1 | G-proteins | GIVAUDAN SA (CH) | 2006-12-07 | — | — | US | disclosed |
| EP-1581555-A2 | G-PROTEINS | Givaudan SA (CH) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004055048-A2 | CHIMERIC ALPHA Q-GUSTDUCIN G-PROTEINS | GIVAUDAN SA (CH) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120177730-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | OPRM1 189/4885OPRD1 556/4885OPRK1 399/4885 |
| US-10610500-B2 | Chemosensory receptor ligand-based therapies | TAS1R2, TAS2R1, GPR119 | OPRM1 189/4885OPRD1 556/4885OPRK1 399/4885 |
| US-10392371-B2 | Compounds useful as modulators of TRPM8 | TRPM8, TRPM4, TRPM6 | OPRM1 111/4885OPRD1 223/4885OPRK1 141/4885 |
| US-11357246-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | OPRM1 2711/4885OPRD1 2112/4885OPRK1 1022/4885 |
| US-20190177308-A9 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | TRPM8, TRPM6, TRPM4 | OPRM1 96/4885OPRD1 240/4885OPRK1 118/4885 |
| US-20190038576-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | OPRM1 189/4885OPRD1 556/4885OPRK1 399/4885 |
| US-20210227863-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | OPRM1 2711/4885OPRD1 2112/4885OPRK1 1022/4885 |
| US-11758933-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | OPRM1 2711/4885OPRD1 2112/4885OPRK1 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.